ADAM10 Proteases and Pancreatic Cancer
DOI:
https://doi.org/10.17140/POJ-1-e003Keywords:
toxicity issues, and therefore additional strategies are being developed to effectively treat PDACAbstract
Pancreatic ductal adenocarcinoma (PDAC) is the 4th leading cause of cancer-related deaths in the United States and is expected to rise to the second rank by 2020.1 The survival rate of PDAC is estimated at less than 5% and the high mortality rate is attributed to the as-ymptomatic progression and aggressive nature of the tumor, which exhibit locally advanced or metastatic disease at the time of diagnosis. Majority of the pancreatic cancers are PDACs and are characterized by a fibrotic tumor stroma.
References
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1): 10-29. doi: 10.3322/caac.20138
Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1997; 15(6): 2403-2413.
Berlin J and Benson AB, 3rd. Chemotherapy: gemcitabine remains the standard of care for pancreatic cancer. Nat Rev Clin Oncol. 2010; 7(3): 135-137. doi: 10.1038/nrclinonc.2010.16
Korc M. Pancreatic cancer-associated stroma production. Am J Surg. 2007; 194(4 Suppl): S84-S86. doi: 10.1016/j.amj-surg.2007.05.004
Marks E, Saif MW and Jia Y. Updates on first-line therapy for metastatic pancreatic adenocarcinoma. JOP: Journal of the pan-creas. 2014; 15(2): 99-102. doi: 10.6092/1590-8577/2279
Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. The New England Journal of Medicine. 2011; 364(19): 1817-1825. doi: 10.1056/NEJMoa1011923
Crawford HC, Dempsey PJ, Brown G, Adam L, Moss ML. ADAM10 as a therapeutic target for cancer and inflammation. Current Pharmaceutical Design. 2009; 15(20): 2288-2299. doi: 10.2174/138161209788682442
Moss ML, Stoeck A, Yan W, Dempsey PJ. ADAM10 as a target for anti-cancer therapy. Current Pharmaceutical Biotechnology. 2008; 9(1): 2-8.
Seals DF and Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 2003; 17(1): 7-30. doi: 10.1101/gad.1039703
Nakamura H, Suenaga N, Taniwaki K, et al. Constitutive and induced CD44 shedding by ADAM-like proteases and membrane-type 1 matrix metalloproteinase. Cancer Research. 2004; 64(3): 876-882. doi: 10.1158/0008-5472.CAN-03-3502
Reiss K, Maretzky T, Ludwig A, et al. ADAM10 cleavage of N-cadherin and regulation of cell-cell adhesion and beta-catenin nuclear signalling. The EMBO journal. 2005; 24(4): 742-752. doi: 10.1038/sj.emboj.7600548
Maretzky T, Reiss K, Ludwig A, et al. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, mi-gration, and beta-catenin translocation. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(26): 9182-9187. doi: 10.1073/pnas.0500918102
Woods NK, Padmanabhan J. Inhibition of amyloid precursor protein processing enhances gemcitabine-mediated cytotoxicity in pancreatic cancer cells. The Journal of Biological Chemistry. 2013. doi: 10.1074/jbc.M113.459255
Gaida MM, Haag N, Gunther F, et al. Expression of A disintegrin and metalloprotease 10 in pancreatic carcinoma. Int J Mol Med. 2010; 26(2): 281-288. doi: 10.3892/ijmm_00000463
Sebens Muerkoster S, Werbing V, et al. Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apop-totic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene. 2007; 26(19): 2759-2768. doi: 10.1038/ sj.onc.1210076
Wente MN, Gaida MM, Mayer C, et al. Expression and potential function of the CXC chemokine CXCL16 in pancreatic ductal adenocarcinoma. Int J Oncol. 2008; 33(2): 297-308. doi: 10.3892/ijo_00000009
Ringel J, Rychly J, Nebe B, et al. CD44, bFGF and hyaluronan in human pancreatic cancer cell lines. Annals of the New York Academy of Sciences. 1999; 880: 238-242. doi: 10.1111/j.1749-6632.1999.tb09528.x
Woods N, Trevino J, Coppola D, Chellappan S, Yang S, Padmanabhan J. Fendiline inhibits proliferation and invasion of pancre-atic cancer cells by interfering with ADAM10 activation and beta-catenin signaling. Oncotarget. 2015; 6(34): 35931-35948.
Wojtalewicz N, Sadeqzadeh E, Weiss JV, et al. A soluble form of the giant cadherin Fat1 is released from pancreatic cancer cells by ADAM10 mediated ectodomain shedding. PloS One. 2014; 9(3): e90461. doi: 10.1371/journal.pone.0090461
Sing A, Tsatskis Y, Fabian L, et al. The atypical cadherin fat directly regulates mitochondrial function and metabolic state. Cell. 2014; 158(6): 1293-1308. doi: 10.1016/j.cell.2014.07.036
Tanoue T, Takeichi M. Mammalian Fat1 cadherin regulates actin dynamics and cell-cell contact. The Journal of Cell Biology. 2004; 165(4): 517-528. doi: 10.1083/jcb.200403006
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Pancreas (POJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.